Tags : Forward

Redx Pharma Receives MHRA’s Positive Response for Restarting its P-I/IIa

Shots: Redx is working on study including lower starting dose and enhanced safety monitoring, assessing safety and tolerability of drug in patients with advance malignancies Redx claims that RXC004 a porcupine inhibitor belong to WNT signalling pathway, seems to be an attractive combination companion for immune-oncology agents  Redx will finalize the suspended protocol for dosing […]Read More